# Glutamatergic Mechanisms: Aim2

> **NCT05401227** · PHASE1 · SUSPENDED · sponsor: **New York State Psychiatric Institute** · enrollment: 120 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Ketamine
- **DRUG:** Ts-134
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05401227
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2022-10-15
- **Primary completion:** 2028-08
- **Final completion:** 2029-08
- **Target enrollment:** 120 (ESTIMATED)
- **Why stopped:** U.S. Department of Health and Human Services OHRP issued an FWA restriction on NYSPI research that included a pause of human subjects research as of June 23, 2023. This study will resume recruitment after OHRP has approved the resumption of research.
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05401227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05401227, "Glutamatergic Mechanisms: Aim2". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05401227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*